HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaadt, B. K. Articles by Hesse, B. Search for Related Content PubMed PubMed Citation Articles by Schaadt, B. K. Articles by Hesse, B.

^99mTc-Aprotinin Scintigraphy in Amyloidosis

¹ Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
² Department of Clinical Physiology and Nuclear Medicine, Hillerød Sygehus, Hillerød, Denmark
³ Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
⁴ Section for Radiopharmacy, Danish Medicines Agency, Copenhagen, Denmark

Changes in the amount and distribution of amyloid lesions have been difficult to monitor because they can usually be demonstrated only by evident symptoms or from a biopsy. The recent progress in the treatment of amyloidosis stresses the need for an early diagnosis and the need for noninvasive monitoring during the course of treatment. To validate ^99mTc-aprotinin scintigraphy, we studied 23 consecutive patients with known or suspected amyloidosis. Methods: ^99mTc-Aprotinin (500–700 MBq) was injected intravenously and whole-body scans, regional images, and SPECT tomograms were obtained 90 min after tracer injection. Results: Focal accumulations of ^99mTc-aprotinin were seen in different organs of 22 patients with a total of 90 lesions, of which 20 were confirmed by biopsy or autopsy. Scintigraphy revealed "silent" amyloid deposits in at least 5 patients who later developed clinical symptoms. Physiologic uptake or excretion in liver and kidneys could not be differentiated from pathologic lesions in those organs. Conclusion: ^99mTc-Aprotinin scintigraphy appears to be a fairly sensitive and specific diagnostic modality in patients with suspected amyloidosis. The technique is noninvasive, and it entails a minimal stress to the patient and is useful for detection of a wide range of lesions.

Key Words: amyloidosis • ^99mTc-aprotinin • scintigraphy

This article has been cited by other articles:

				M. Demeule, A. Regina, C. Che, J. Poirier, T. Nguyen, R. Gabathuler, J.-P. Castaigne, and R. Beliveau Identification and Design of Peptides as a New Drug Delivery System for the Brain J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1064 - 1072. [Abstract] [Full Text] [PDF]

				J. S. Wall, S. J. Kennel, M. Paulus, J. Gregor, T. Richey, J. Avenell, J. Yap, D. Townsend, D. T. Weiss, and A. Solomon Radioimaging of Light Chain Amyloid with a Fibril-Reactive Monoclonal Antibody J. Nucl. Med., December 1, 2006; 47(12): 2016 - 2024. [Abstract] [Full Text] [PDF]

				E. Perugini, P. L. Guidalotti, F. Salvi, R. M.T. Cooke, C. Pettinato, L. Riva, O. Leone, M. Farsad, P. Ciliberti, L. Bacchi-Reggiani, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1076 - 1084. [Abstract] [Full Text] [PDF]